Summary Using a quantitative cytochemical technique for measuring ,B-glucuronidase activity in the peripheral nerves of mice, we have investigated the effectiveness of four potential adjuncts for reducing the dose limiting neurotoxicity of misonidazole (MISO) in the clinic.
It is now widely appreciated that the full radiosensitising potential of the nitroimidazole, misonidazole (MISO), will not be realised clinically because of dose-limiting peripheral neuropathy (Dische et al., 1977; Urtasan et al., 1977) . This has prompted the search for ways to either develop less toxic alternatives, or ameliorate the toxicity of MISO itself. The developmental approach has concentrated on nitroimidazoles of reduced octanolwater partition coefficient: for it has been reported that such compounds, though retaining their ability to penetrate tumours, have a reduced capacity to penetrate the central nervous system (Brown & Workman, 1980) . Indeed, we have previously described a relationship between the partition coefficient of nitroimidazoles and their neurotoxicity in mice (Clarke et al., 1982a) . In the present studies we have turned our attention to the other approach for overcoming neurotoxicity, the use of adjuncts to ameliorate the toxicity of MISO.
The incidence of MISO induced neurotoxicity in man has been correlated with the exposure to the drug as expressed by the area under the curve (AUC) of plasma concentration with time (Dische et al., 1979) . Assuming the radiosensitising action of MISO is dependent not on this total exposure dose, but to the peak serum level obtainable at the time of irradiation, one approach to reducing neurotoxicity would be to combine MISO with an agent that altered its pharmacokinetics towards a Correspondence: P.W. Sheldon Received 19 July 1983; accepted 4 November 1983. shorter half-life but unaltered peak concentration. In mice, phenytoin and phenobarbitone have been shown to achieve this by increasing the rate of oxidative demethylation in the liver (Workman, 1979) , Dexamethasone phosphate, though not influencing the concentration of MISO in the blood of mice, has been observed to reduce the concentration in the brain, possibly by reducing the cerebrovascular permeability and/or blood flow (Workman, 1980a) . Fortuitously, all these drugs have been used as either anti-convulsants or antiinflammatory agents in a number of clinical trials with MISO of patients with gliomas (Bleehen, 1980; Wasserman et al., 1980) . We report here the influence of these drugs (i.e. phenytoin, phenobarbitone and dexamethasone) on the neurotoxicity of MISO, as assayed by quantitative cytochemistry of the increased content of the\ lysosomal enzyme, f-glucoronidase, in the peripheral nerves of mice (Clarke et al., 1980) . The drugs were administered at doses similar to those employed in the pharmacokinetic studies of Workman (1979 Workman ( , 1980a . We have extended the study to include the non-steroid anti-inflammatory agent flurbiprofen which has been reported to reduce the cytotoxic action of MISO in vitro, possibly by inhibiting its catabolism to toxic products . Further, because dexamethasone has been reported to protect V-79 cells in vitro against x-irradiation , an effect that would reduce any therapeutic benefit accruing from combining this drug with MISO treatment, we have investigated its effects on the radiation response of a murine tumour in vivo.
Materials and methods
Mice Inbred, 8-10 week old, female, C57BI/Cbi mice were used in the pharmacokinetic and neurotoxicity studies and inbred, 6-8 week old, female, WHT/Cbi mice were used in the radiation study. (Sampson, 1969) AUC=A/fl Neurotoxicity The mice were sacrificed 4 weeks after the commencement of MISO dosing and their tibial nerves were assayed cytochemically for f,-glucuronidase activity using a micro-densitometer as described previously (Clarke et al., 1982b) . The resulting enzyme activities are expressed as integrated optical density (OD) units x 103 and increase in magnitude in line with the severity of the neurotoxic response.
Drugs
Radiation study Mice were inoculated s.c. over the sacral region of the back with anaplastic MT tumour cells. When the resulting tumours attained a mean diameter of 6-7mm, the mice (except for control animals) were given a single i.p. dose of 400mgkg-1 dexamethasone. At intervals of up to 24 h thereafter, the tumours were locally X-irradiated in a manner similar to that described previously (Sheldon & Hill, 1977) . Eighteen hours later the tumours were excised and their responses assayed by soft-agar cloning (Sheldon et al., 1982) .
Results
The increase in ,B glucuronidase activity in sciatic nerves as a function of MISO dosage is shown in Figure 1 . At 80mgkg-1 per dose MISO produced an insignificant increase in enzyme activity from that observed in the untreated controls, but at 300mgkg-' per dose (as used here in most studies) the activity was approximately double that of the controls. This MISO-induced elevation in figlucuronidase activity has previously been shown to be a measure of neurotoxicity (Clarke et al., 1980) . The effects of phenytoin, phenobarbitone and dexamethasone pretreatments on the pharmacokinetics of MISO are shown in Table I . Under the dosing regimes employed, none of the agents altered the peak blood content of MISO from the non-pretreated control value, but all three agents did shorten the half-life. A similar pattern is evident in the brain tissue although here dexamethasone also reduced the peak brain content of MISO. Thus in the hypothesis outlined above, all three agents would, under the dosing conditions used, have the potential for reducing MISO neurotoxicity.
It had been planned in the aforementioned pharmacokinetic study to measure the demethylated metabolite of MISO, DEMISO. However, this was not possible because the DEMISO peak was not clearly separable from the solvent front, although the MISO and internal standard (Ro 07-0741) peaks were well delineated. The inability to measure (Workman, 1979; 1980a; personal communication) , and in this animal system DEMISO is known to be considerably less toxic than MISO (Adams et al., 1983) . The effects of MISO and/or the liver microsomal enzyme inducers, phenytoin and phenobarbitone, on the ,B-glucuronidase activity in the nerve are shown in Figure 2 . Phenytoin (40mg kg-per dose) and phenobarbitone (80mg kg-1 per dose) were given daily for 5 days before MISO on either Day 8a or 12b. Dexamethasone (0.5mgkg-1 per dose) was given daily for 8 days with the last dose 2-h before the MISO. S.e.m.'s are shown in parenthesis.
Ct6peak" concentration is that measured at the earliest sampling time of 15 min. The effects of MISO and/or the non-steroid antiinflammatory agent flurbiprofen on the f,-glucuronidase activity in the nerve are shown in Table II . In all three experiments the MISO doses were administered 2.5 h after flurbiprofen doses. This interval was selected on account that it has been reported to be effective in the flurbiprofen protection against MISO cytotoxicity in vivo (Millar et al., 1983 Conversely, in the second experiment (right-hand panel) it can be seen that, relative to the MISO alone treated group, the low dose of dexamethasone has no effect if given only during the same week as MISO, but suppresses the induced enzyme activity by 60% if given over the week previous to MISO.
As the dexamethasone alone did not induce any significant change in enzyme activity from that observed for the untreated control mice, this reduction in MISO-induced enzyme activity (to 27.7 integrated OD x 103) can by reference to Figure 1 be equated to a reduction in dose from 300 to -120mgkg-1, a DMF of 0.4. 
Discussion
The mechanism by which MISO produces its neurotoxic effects is unknown. The toxicity could stem from the drug itself, or a metabolite. It is believed that under well oxygenated conditions (such as found in the liver) the drug undergoes oxidative metabolism to form the demethylated metabolite DEMISO, whereas under poorly oxygenated conditions (such as found in tumours) it undergoes reductive metabolism to form the amine (Workman, 1980b) . Thus, any agent that promotes or inhibits the metabolism of MISO could interfere with its neurotoxic potential. We have reported here our findings with four such agents: phenytoin and phenobarbitone which are believed to increase the oxidative metabolism of MISO (Workman, 1979) , and dexamethasone and flurbiprofen, which are believed to inhibit its reductive metabolism (Millar et al., 1983) .
The effects of three of these agents (phenytoin, phenobarbitone, dexamethasone) on the pharmacology of MISO have been studied here and, under the dosing regimes employed, none altered the "peak" concentration of MISO in the blood, but dexamethasone alone did result in a small reduction in the brain "peak" (Table I) . However, all the agents did reduce the clearance half-life in both tissues and hence resulted in smaller drug exposures as expressed as areas under the curve (AUC) of MISO tissue concentration as a function of time. On the premise that the dose limiting neuropathy of MISO in man is related to the AUC (Dische et al., 1979) , it follows that these agents should have rendered MISO less neurotoxic here. This was not always so, for although dexamethasone did reduce neurotoxicity (Figure 3) , phenobarbitone did not ( Figure 2B ) and the results with phenytoin were equivocal (Figure 2A) . Hence, in the mouse AUC may not be the critical factor. Indeed the importance of AUC in the clinic has also been brought into question with the recent observation that DEMISO, despite its reduced AUC, appears no less neurotoxic than MISO (Dische et al., 1982) .
The dose of MISO used in the present studies was chosen because, though sufficient to double the ,B-glucuronidase activity in nerves, it was thought Interval (h)
akin to the clinical situation in that it was insufficient to result in saturation of the liver metabolic enzymes (Gibson, 1982 its toxicity ( Figure 2B ). The use of an inappropriate dosing regime is thought an unlikely explanation for this failure; though the phenobarbitone was only given through the week previous to that of MISO treatment, and liver enzyme deinduction has been reported to occur at a similar rate as induction (Marshall & McLean, 1969) , modified pharmacokinetics were observed at the start and (albeit to a lesser extent) the end of MISO treatment (Table I) . It should be noted that whilst our pharmacological data are in general accord with those reported by Workman (1979, 1980a) , the dose of dexamethasone we required to produce a reduction in MISO brain levels was markedly lower, perhaps because of the different mouse strains used. The fact that the dexamethasone did result here in such marked reductions in the AUCs for both brain and blood would tend to indicate that the proposed mechanism of an inhibition of MISO metabolism seems unlikely. Jasani (1979) has reported that dexamethasone causes capillary vasoconstriction and reduced capillary permeability, and this could account for the reduced levels of MISO seen in the brain. Whatever the mechanism, dexamethasone did prove very effective here at reducing MISO toxicity as measured at week 4 after the commencement of MISO dosing. However, it should be noted that dexamethasone is known to delay the proliferation responses associated with inflammation (Spain, 1961) and so, although not investigated here, the agent could have delayed the enzyme changes normally associated with the MISO induced nerve damage. Indeed the enzyme fl-glucuronidase is a marker for both Schwann cell increase and macrophage infiltration (Hollinger & Rossiter, 1952; McCaman & Robins, 1959) .
The data for the other anti-inflammatory agent, the non-steroid flurbiprofen, also indicate a reduction in the toxicity of MISO, but the effect is smaller than seen with dexamethasone despite the use of much higher drug doses. Unlike dexamethasone, which was effective only when given the week before MISO treatment, flurbiprofen was also effective when given only 2.5h before each MISO dose.
In the present study, the effectiveness of the agents at reducing the neurotoxicity of MISO are in decreasing order, dexamethasone, phenytoin, flurbiprofen and phenobarbitone. Caution should be exercised in translating these observations in mice to the clinic. Further, it should be borne in mind that dexamethasone, apparently the most effective agent here at reducing MISO neurotoxicity, may offer no therapeutic benefit since it has also been reported to have the detrimental effects of increasing the acute toxicity of MISO (Workman, 1980a) and protecting V-79 cells in vitro against X-irradiation . However, Millar did predict that such radioprotection would only occur in those cells that contained the appropriate steroid receptors, and this may account for why Brock et al. (1983) , whilst observing radioprotection of V-79 cells, did not observe it in three other in vitro cell lines. Similarly, albeit in a limited study, we observed no radioprotection by dexamethasone of the anaplastic MT tumour in vivo (Figure 4) . Consequently, giving dexamethasone as an adjunct to MISO radiosensitiser therapy may be either beneficial or detrimental depending on tumour cell type.
We conclude that under the conditions employed here, dexamethasone, phenytoin, flurbiprofen, but not phenobarbitone, were effective at reducing the toxicity of MISO. However, this protection need not have a pharmacological basis, at least not in terms of blood or brain clearance half-life or AUC.
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